Mitomycin-c Application for PRK

Shahid Beheshti University of Medical Sciences90 enrolled

Overview

To evaluate the safety and efficacy of 5 seconds mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for patients with low myopia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Conditions

Myopia

Interventions

mitomycin-CDRUG

PlaceboDRUG

balanced salt solution (BSS)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * The inclusion criteria was ablation depth less than 65 µm, * a stable refractive error for at least 1 year * corrected distance visual acuity (CDVA) of 0.1 LogMAR or better. Exclusion Criteria: * Patients with keratoconus suspect, * excessive dry eyes, * impaired wound healing processes, * lenticular changes, * corneal dystrophy, * history of ocular surgery, * anterior or posterior uveitis, * glaucoma and retinal diseases were excluded.

Locations (1)

Ophthalmic Research Center

Tehran, Tehran Province, Iran

Outcomes

Primary Outcomes

Central corneal endothelial cell density (ECD) 6 months after the PRK

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.